Latest fraudulent alert - last updated on Apr 2023. To find out more information and how to protect yourself, please click here.

Investment Institute

What impact could robotic surgery have on the future of healthcare?

  • 26 March 2021 (5 min read)

Key points

  • Technological advancements have seen the application of surgical robots broaden over time to include general surgery and delicate operations
  • Only 4% of surgery globally is done with robots, with most of these procedures performed in the US
  • We believe the applications in robotic surgery will continue to widen by both procedure type and region, creating compelling investment opportunities

Surgical robots have been around since the 1980s, with the Puma 560 used in 1985 by Kwoh et al to perform neurosurgical biopsies and non-laparoscopic surgery with greater precision.1

As technology and surgical developments have rapidly advanced over the years, so too has the general perception of robots – moving from science fiction to cutting-edge technology that could ultimately revolutionise healthcare.

More than 30 years later, the influence of surgical robots in operating rooms is growing at pace. Only 4% of surgery globally is done with robots2 , with most of these procedures performed in the US. While this figure may currently sound small, we believe this highlights the huge growth potential for geographic expansion in the coming years.

The benefits of robotic surgery include:

  • Enhanced dexterity: Surgeons are able to operate in very tight spaces in a body that would otherwise only be accessible through open surgery;
  • Greater precision and control: Surgical robots help surgeons with the positioning and manipulation of surgical instruments;
  • Shorter hospital stays: The smaller incisions will likely mean faster recovery times for patients and, generally, lower readmission rates.
  • IFlTIEt3b2gsIEogSG91LCBFQSBKb25ja2hlZXJlIGF0IGFsLiBBIHJvYm90IHdpdGggaW1wcm92ZWQgYWJzb2x1dGUgcG9zaXRpb25pbmcgYWNjdXJhY3kgZm9yIENUIGd1aWRlZCBzdGVyZW90YWN0aWMgYnJhaW4gc3VyZ2VyeS4gSUVFRSBUcmFucyBCaW9tZWQgRW5nIDE5ODg=
  • QmFuayBvZiBBbWVyaWNhIE1lcnJpbGwgTHluY2gsIGdsb2JhbCByZXNlYXJjaCBlc3RpbWF0ZXMsIERlY2VtYmVyIDIwMjA=

Examples of procedures fueling innovation in robotic surgery

Over time, the application of surgical robots has significantly widened - from general laparoscopic procedures such as hernia and colorectal surgery to delicate operations on the heart and spine, knee replacements and removing brain tumours. Below are some examples of companies leading innovation in robotic surgery:

General surgery

At the forefront of the developments in these types of procedures is Intuitive Surgical*, which manufactures robotic-assisted medical equipment to support doctors and hospitals in minimally invasive surgery. It pioneered the groundbreaking da Vinci system, with almost 6,000 in existence around the world and a surgeon starting a da Vinci procedure every 25.4 seconds. In 2020, da Vinci Surgical Systems were used to perform 1.2mn procedures, a marginal increase from 2019 – and a significant figure, given that some surgeries had been postponed due to the COVID-19 pandemic.

Launched in 1998, Intuitive Surgical’s da Vinci system was one of the first robotic-assisted systems approved by the US Food and Drug Administration (FDA) for general laparoscopic surgery. Intuitive’s status as a key player is backed up by a comprehensive training programme for academics and future doctors, and reinvestments in research and development – its annual spend on the latter has almost tripled from $197mn in 2015 to over $500mn in 2019 and 2020.

Spine surgery

Globus Medical* is a leading medical device manufacturer, focusing on musculoskeletal implants that provide spine care solutions for patients. One of its solutions is the ExcelsiusGPS, a robotic arm with complete navigation capabilities in one adaptable platform for accurate alignment in spine surgery. It means surgeons can visualise, plan and navigate patient anatomy – as well as receive navigation feedback throughout the procedure - in real-time. The company has also developed orthopaedic trauma solutions in recent years to diversify beyond the spine market.

Knee replacements

The global share of older people (60+) is expected to increase by 42% from 2018 to 2030 – five times faster than the under 60 population.3 As you age, knee joints run the risk of becoming worn or damaged over time, with knee replacement surgery generally carried out on the 60-80 age bracket.4 Many people also live more active lifestyles into older age, compared to previous generations. This means more people may find they need knee surgery in their later years.

Zimmer Biomet* is a US healthcare company that specialises in knee surgery. Its ROSA Knee robotic technology is designed to help a specially trained surgeon tailor the placement of knee implants. Zimmer has also developed its mymobility app, in collaboration with Apple, to inform care decisions and further enhance the communication between patients and their surgeons.

Huge growth potential around the world

The global market for robotic surgery equipment is expected to achieve a compound annual growth rate of 30% until 2023.5 The COVID-19 pandemic meant that hospitals around the world were forced to delay many non-urgent surgeries in which robots could have supported. However, going forward, the containment of the disease through the rollout of vaccines will likely normalise hospitals’ operational capacity, leading to a surge in postponed robotic surgeries being performed.

Another reason for optimism is likely to come in the form of new market entrants, with the low market penetration allowing different companies to develop solutions that address a range of issues. For example, Johnson & Johnson* has a growing market presence, particularly with its acquisition of Auris Health – a robotic technology platform focused on lung diagnostics and procedures. Elsewhere, Medtronic*, a global medical device manufacturer, is in the process of developing a surgical robot.

With new entrants comes the potential for more innovation, thanks to disruptive technology like image-guided robotic interventions and enhanced motion control for greater precision. Coupled with 5G and AI6 , developments in these areas will likely increase the types of robotic-assisted surgical procedures performed in the future – for example, the removal of tumours from parts of the body that would otherwise be difficult to reach. As a result, we expect this will create compelling investment opportunities within robotic surgery over the coming years.

  • QmFuayBvZiBBbWVyaWNhIE1lcnJpbGwgTHluY2ggU2lsdmVyIERvbGxhciAvIExvbmdldml0eSBSZXBvcnQsIE1heSAyMDE2
  • TkhTIFVLLCBBdWd1c3QgMjAxOQ==
  • IEludGVybmF0aW9uYWwgRmVkZXJhdGlvbiBvZiBSb2JvdGljcyAyMDIw
  • QUkgcmVmZXJzIHRvIGFydGlmaWNpYWwgaW50ZWxsaWdlbmNl

Related Articles


US cements itself as the global centre of tech innovation

  • by Tom Riley, Pauline Llandric, and others
  • 29 May 2024 (5 min read)

How generative AI is transforming e-commerce

  • by AXA IM Investment Institute
  • 26 April 2024 (5 min read)

More than meets the AI? Exploring key drivers for tech in 2024

  • by AXA Investment Managers
  • 30 January 2024 (7 min read)


    This document is for informational purposes only and does not constitute investment research or financial analysis relating to transactions in financial instruments as per MIF Directive (2014/65/EU), nor does it constitute on the part of AXA Investment Managers or its affiliated companies an offer to buy or sell any investments, products or services, and should not be considered as solicitation or investment, legal or tax advice, a recommendation for an investment strategy or a personalized recommendation to buy or sell securities. 

    It has been established on the basis of data, projections, forecasts, anticipations and hypothesis which are subjective. Its analysis and conclusions are the expression of an opinion, based on available data at a specific date. 
    All information in this document is established on data made public by official providers of economic and market statistics. AXA Investment Managers disclaims any and all liability relating to a decision based on or for reliance on this document. All exhibits included in this document, unless stated otherwise, are as of the publication date of this document. 
    Furthermore, due to the subjective nature of these opinions and analysis, these data, projections, forecasts, anticipations, hypothesis, etc. are not necessary used or followed by AXA IM’s portfolio management teams or its affiliates, who may act based on their own opinions. Any reproduction of this information, in whole or in part is, unless otherwise authorised by AXA IM, prohibited. 


    This website is published by AXA Investment Managers Asia Limited (“AXA IM HK”), an entity licensed by the Securities and Futures Commission of Hong Kong (“SFC”), for general circulation and informational purposes only. It does not constitute investment research or financial analysis relating to transactions in financial instruments, nor does it constitute on the part of AXA Investment Managers or its affiliated companies an offer to buy, sell or enter into any transactions in respect of any investments, products or services, and should not be considered as solicitation or investment, legal, tax or any other advice, a recommendation for an investment strategy or a personalised recommendation to buy or sell securities under any applicable law or regulation. It has been prepared without taking into account the specific personal circumstances, investment objectives, financial situation, investment knowledge or particular needs of any particular person and may be subject to change at any time without notice. Offering may be made only on the basis of the information disclosed in the relevant offering documents. Please consult independent financial or other professional advisers if you are unsure about any information contained herein.

    Due to its simplification, this publication is partial and opinions, estimates and forecasts herein are subjective and subject to change without notice. There is no guarantee such opinions, estimates and forecasts made will come to pass. Actual results of operations and achievements may differ materially. Data, figures, declarations, analysis, predictions and other information in this publication is provided based on our state of knowledge at the time of creation of this publication. Information herein may be obtained from sources believed to be reliable. AXA IM HK has reasonable belief that such information is accurate, complete and up-to-date. To the maximum extent permitted by law, AXA IM HK, its affiliates, directors, officers or employees take no responsibility for the data provided by third party, including the accuracy of such data. This material does not contain sufficient information to support an investment decision. References to companies (if any) are for illustrative purposes only and should not be viewed as investment recommendations or solicitations.

    All investment involves risk, including the loss of capital. The value of investments and the income from them can fluctuate and that past performance is no guarantee of future returns, investors may not get back the amount originally invested. Investors should not make any investment decision based on this material alone. 

    Some of the services listed on this Website may not be available for offer to retail investors.

    This Website has not been reviewed by the SFC. © 2024 AXA Investment Managers. All rights reserved.